or Try an Advanced Search...

    Technical Analysis for ERNA - Eterna Therapeutics Inc.

    Grade Last Price % Change Price Change
    F 0.54 -12.48% -0.08
    ERNA closed down 12.81 percent on Wednesday, November 20, 2024, on 5.35 times normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical ERNA trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish -12.48%
    Stochastic Buy Signal Bullish -12.48%
    Volume Surge Other -12.48%
    Lower Bollinger Band Walk Weakness -12.48%
    New 52 Week Low Weakness -12.48%
    Wide Bands Range Expansion -12.48%
    Below Lower BB Weakness -12.48%
    Lower Bollinger Band Touch Weakness -12.48%
    Oversold Stochastic Weakness -12.48%
    Volume Surge Other -23.69%
    Older End-of-Day Signals for ERNA ...

       Recent Intraday Alerts

    Alert Time
    Possible Inside Day about 1 hour ago
    3x Volume Pace about 2 hours ago
    60 Minute Opening Range Breakdown about 5 hours ago
    Down 10% about 5 hours ago
    2x Volume Pace about 5 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    ERNA Chart by TradingView
    Basic chart:

    Profile

    Eterna is focused on developing advanced therapies using state-of-the-art mRNA cell engineering technology. Its mission is to realize the potential of cell engineering to provide patients with transformational new medicines. The Company has in-licensed a portfolio of over 100 patents covering key cell engineering technologies, including what it believes are the most widely used methods for therapeutic gene editing currently in clinical development. Eterna has multiple next-generation cell and gene-editing therapies in preclinical development for various indications.
    Classification
    Sector: Consumer Cyclical
    Industry: Broadcasting - TV
    Keywords: Cancer Clinical Medicine Immunology Immune System Immunotherapy Natural Killer Cell T Cell Dendritic Cell

    Is ERNA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 14 Eterna Therapeutics regains Nasdaq compliance
    Nov 14 Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing
    Oct 30 Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success
    Oct 18 Eterna, Factor announce license, collaboration agreement
    Oct 17 Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases
    See more ERNA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.625
    52 Week Low 0.5231
    Average Volume 62,450
    200-Day Moving Average 1.70
    50-Day Moving Average 1.08
    20-Day Moving Average 0.99
    10-Day Moving Average 0.91
    Average True Range 0.12
    RSI (14) 24.81
    ADX 21.42
    +DI 12.97
    -DI 33.38
    Chandelier Exit (Long, 3 ATRs) 0.88
    Chandelier Exit (Short, 3 ATRs) 0.90
    Upper Bollinger Bands 1.29
    Lower Bollinger Band 0.68
    Percent B (%b) -0.11
    BandWidth 62.09
    MACD Line -0.10
    MACD Signal Line -0.06
    MACD Histogram -0.0417
    Fundamentals Value
    Market Cap 3.33 Million
    Num Shares 5.41 Million
    EPS -3.96
    Price-to-Earnings (P/E) Ratio -0.16
    Price-to-Sales 175.64
    Price-to-Book 2.43
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.88
    Resistance 3 (R3) 0.88 0.79 0.84
    Resistance 2 (R2) 0.79 0.72 0.79 0.82
    Resistance 1 (R1) 0.70 0.68 0.66 0.70 0.81
    Pivot Point 0.61 0.61 0.59 0.61 0.61
    Support 1 (S1) 0.53 0.55 0.48 0.53 0.42
    Support 2 (S2) 0.44 0.50 0.44 0.41
    Support 3 (S3) 0.35 0.44 0.39
    Support 4 (S4) 0.35